Insight Molecular Diagnostics Inc. Common Stock IMDX Income Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| -$109K-29.8% | -$84K-61.5% | -$52K+37.3% | -$83K+60.3% | ||
| $4.06M+116% | $1.88M+25.1% | $1.5M+56.9% | $958K-87.6% | ||
| $1.75M+65.7% | $1.05M+5.1% | $1M+13.9% | $880K-83.0% | ||
| $2.31M+179% | $828K— | —— | $82K-96.8% | ||
| 57%+12.9pp | 44%— | —— | 8.6%-24.6pp | ||
| $15.91M+61.7% | $9.84M+5.9% | $9.29M+27.3% | $7.3M-46.4% | ||
| $6.34M+60.8% | $3.94M+41.1% | $2.8M+147% | $1.13M-89.9% | ||
| $10.63M+4.2% | $10.2M-8.7% | $11.18M-48.9% | $21.88M-2.0% | ||
| $53.43M-13.5% | $61.78M+142% | $25.55M+42.1% | $17.98M-67.4% | ||
| -$51.12M+16.2% | -$61.04M-143% | -$25.14M-39.7% | -$18M+75.7% | ||
| -1,260.8%+1,984pp | -3,245.1%-1,573pp | -1,672.4%+206pp | -1,878.6%-918pp | ||
| $902K+139% | $378K+34.5% | $281K+146% | -$615K-172% | ||
| $0— | $0— | —— | —— | ||
| -$50.22M+17.2% | -$60.66M-118% | -$27.78M+61.9% | -$72.9M-13.7% | ||
| -1,238.5%+1,987pp | -3,225%-1,377pp | -1,848.4%+5,761pp | -7,609.8%-6,780pp | ||
| -$1.64+65.6% | -$4.77-34.4% | -$3.55+68.4% | -$11.24-2,242% | ||
| -$48.93M+17.8% | -$59.57M-153% | -$23.54M-43.0% | -$16.47M+76.5% | ||
| -1,206.8%+1,960pp | -3,166.7%-1,600pp | -1,566.5%+153pp | -1,719.1%-813pp | ||
| -$51.12M+16.2% | -$61.04M-143% | -$25.14M-39.7% | -$18M+75.7% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Insight Molecular Diagnostics Inc. Common Stock's revenue?
- Insight Molecular Diagnostics Inc. Common Stock (IMDX) generated $1.9M in revenue over the trailing twelve months, down 49.3% year over year.
- Is Insight Molecular Diagnostics Inc. Common Stock profitable?
- Insight Molecular Diagnostics Inc. Common Stock is not currently profitable: it reported a net loss of $47.8M over the trailing twelve months, a -2454.6% net margin.
- What are Insight Molecular Diagnostics Inc. Common Stock's profit margins?
- Gross margin is 51.3% and operating margin is -2500.7%, with a -2454.6% net margin.
- What is Insight Molecular Diagnostics Inc. Common Stock's earnings per share?
- Insight Molecular Diagnostics Inc. Common Stock's diluted EPS over the trailing twelve months is $-1.50.
- Where does Insight Molecular Diagnostics Inc. Common Stock's income statement data come from?
- Every line is extracted from Insight Molecular Diagnostics Inc. Common Stock's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
